The FDA has approved the use of Vyvanse (lisdexamfetamine dimesylate capsules, from Shire) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults. In a double-blind clinical study of 414 adults, patients with ADHD experienced significant improvements in symptom control within one week of Vyvanse treatment, compared to placebo.
Vyvanse is also indicated for the treatment of ADHD in children 6-12 years of age and is available in 30mg, 50mg, and 70mg dosage strengths. Additional dosage strengths of 20mg, 40mg, and 60mg were approved and are expected to be available by summer 2008.
For more information call (800) 828-2088 or visit www.vyvanse.com.